Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Update

Astellas Pharma Inc. (OTCMKTS:ALPMY) saw a large decrease in short interest during the month of June. As of June 15th, there was short interest totaling 16,568 shares, a decrease of 37.3% from the May 31st total of 26,405 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily volume of 474,815 shares, the short-interest ratio is presently 0.0 days.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Jefferies Financial Group raised shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 24th. Zacks Research raised Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 23rd. Two investment analysts have rated the stock with a Strong Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy”.

Astellas Pharma Stock Down 2.5%

OTCMKTS:ALPMY opened at $13.04 on Thursday. Astellas Pharma has a twelve month low of $9.22 and a twelve month high of $17.35. The company has a market cap of $23.60 billion, a price-to-earnings ratio of 12.14 and a beta of 0.07. The stock has a fifty day simple moving average of $14.01 and a 200-day simple moving average of $14.66. The company has a current ratio of 1.09, a quick ratio of 0.84 and a debt-to-equity ratio of 0.23.

Astellas Pharma (OTCMKTS:ALPMY) last posted its quarterly earnings results on Monday, April 27th. The company reported $0.33 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.14. The firm had revenue of $3.38 billion for the quarter, compared to analysts’ expectations of $3.28 billion. Astellas Pharma had a net margin of 13.66% and a return on equity of 24.19%. Analysts anticipate that Astellas Pharma will post 1.25 EPS for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).